Filana Therapeutics, Inc. Common Stock (FLNA)

• Market cap: $83.6M
• 1 day: -1.7%
• 5 days: 5.49%
• 1 month: -13.5%
• 3 months: -13.07%
• 6 months: -59.77%
• Year to date: -17.22%
• 1 year: 20.14%
• 5 years: -94.91%
• 10 years: -89.3%
• Sector: Healthcare
• Industry: Biotechnology

About: Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.

Employees: 20